Best’s disease usually develops in the first decade of life, but may not cause symptoms until later. Symptoms are blurry, distorted, or missing central vision. It can be diagnosed by a dilated eye exam with an ophthalmoscope. In this disease, the macula typically looks like a “sunny side up egg,” which can later burst, releasing fluid into the macula and causing macular degeneration. Additional helpful tests are optical coherence tomography (OCT), a type of noninvasive retinal imaging technique that generates a cross-section picture of the retina in a few seconds, and the electro-oculogram (EOG), which measures the electrical potential across the retina.
What Causes Best’s Disease?
The gene responsible for Best’s disease is called bestrophin, or vitelliform macular dystrophy 2 (VMD2). Usually, mutations are dominant, so that the children of an affected parent have a 50 percent chance of getting the disease. The normal function of bestrophin is to conduct ions, like calcium and chloride, across the membrane of a cell type in the back of the retina, called the retinal pigment epithelium.
Are There Treatments for Best’s Disease?
Researchers are trying to develop gene and other therapies based on this knowledge, but currently there are no specific treatments for this disease.
Research Update on Best’s Disease
There has been significant progress in research efforts to develop a gene therapy treatment for Best’s disease. Gene therapy for retinal diseases is now considered a viable approach, as the FDA recently approved retinal gene therapy for an inherited form of blindness called Leber’s congenital amaurosis. The same technical approach, using a non-disease-causing virus called adeno-associated virus (AAV) should now be translatable to additional retinal diseases.
Proof of principle that AAV gene therapy will work for Best’s disease is provided by the treatment of dogs with Best’s disease in an article published recently by investigators from the University of Pennsylvania (UPenn) and the University of Florida (UF).
A company called Ophthotech has a licensing agreement with the University of Pennsylvania to develop these findings into a treatment for patients. They hope to begin clinical trials in 2021. Also, once a clinical trial begins, information on the trial can be found at our Antidote clinical trial search tool or on clinicaltrials.gov.
With more research and clinical trials, the future is bright for Best’s disease.
- Macular Degeneration Toolkit (Helpful Information to Understand and Manage Macular Degeneration)
- Expert Information on Macular Degeneration (Articles)
- BrightFocus Chats (Audio Presentations on Macular Degeneration)
- Macular Degeneration Research News (Newsletters)
- Juvenile Macular Degeneration (Article)
- Retinal Imaging for Diagnosing and Treating Macular Degeneration (Article)
- Clinical Trials: Your Questions Answered (Publication)
This content was last updated on: November 16, 2020
The information provided here is a public service of the BrightFocus Foundation and should not in any way substitute for personalized advice of a qualified healthcare professional; it is not intended to constitute medical advice. Please consult your physician for personalized medical advice. BrightFocus Foundation does not endorse any medical product, therapy, or resources mentioned or listed in this article. All medications and supplements should only be taken under medical supervision. Also, although we make every effort to keep the medical information on our website updated, we cannot guarantee that the posted information reflects the most up-to-date research.
These articles do not imply an endorsement of BrightFocus by the author or their institution, nor do they imply an endorsement of the institution or author by BrightFocus.
Some of the content may be adapted from other sources, which will be clearly identified within the article.